Search results for "malattie"

showing 10 items of 1963 documents

Retrograde Recanalization of Chronic Total Occlusions in Europe: Procedural, In-Hospital, and Long-Term Outcomes From the Multicenter ERCTO Registry.

2015

BACKGROUND A retrograde approach improves the success rate of percutaneous coronary interventions (PCIs) for chronic total occlusions (CTOs). OBJECTIVES The authors describe the European experience with and outcomes of retrograde PCI revascularization for coronary CTOs. METHODS Follow-up data were collected from 1,395 patients with 1,582 CTO lesions enrolled between January 2008 and December 2012 for retrograde CTO PCI at 44 European centers. Major adverse cardiac and cerebrovascular events were defined as the composite of cardiac death, myocardial infarction, stroke, and further revascularization. RESULTS The mean patient age was 62.0 +/- 10.4 years; 88.5% were men. Procedural and clinical…

MaleTime FactorsIncidenceMiddle AgedCoronary AngiographySettore MED/11 - Malattie Dell'Apparato CardiovascolareHospitalsEuropeElectrocardiographyPercutaneous Coronary InterventionPostoperative ComplicationsTreatment OutcomeCoronary Occlusionchronic total occlusionsJ-CTO scoreChronic DiseaseHumansretrograde PCI revascularizationFemaleHospital MortalityProspective StudiesRegistrieschronic total occlusionFollow-Up StudiesJournal of the American College of Cardiology
researchProduct

In-hospital stay of patient with acute coronary syndrome with or without diabetes mellitus

2009

Aim. Type 2 diabetes is associated with an increase in the risk of coronary heart disease, by a factor of two to four. The scientific community has suggested that all patients with diabetes could be treated as if they had a prior coronary heart disease. Methods. A computer review of 11-year prevalence (from 1991 to 2002) of type 2 diabetes among 3 242 patients admitted to the Intensive Coronary Care Unit of the Division of Cardiology of the University Hospital "Paolo Giaccone", Palermo, was carried out, with the diagnosis of ST elevation myocardial infarction (STEMI) (51%), non ST elevation myocardial infarction (NSTEMI) (6%) or unstable angina (UA) (43%). Results. Prevalence of type 2 diab…

MaleTime FactorsMyocardial InfarctionLength of StayMiddle AgedSettore MED/11 - Malattie Dell'Apparato CardiovascolareDiabetes ComplicationsElectrocardiographyIntensive Care UnitsDiabetes Mellitus Type 2coronary syndrome diabetes mellitusRisk FactorsPrevalenceHumansFemaleAcute Coronary SyndromeSicilyAgedRetrospective Studies
researchProduct

Short term prognostic role of NT-proBNP in patients after myocardial infarction

2009

Aim. The clinical and prognostic role of cardiac natriuretic peptides (CNP) in patients with heart failure is well known; recently, several studies have evaluated the possibility of using CNP to evaluate their potential prognostic role in patients with acute coronary syndromes (ACS). The aim of this study was to evaluate the short term prognostic value of NT-proBNP in 70 patients admitted for ACS. Methods. The authors studied 70 patients with ACS, evaluating, at admission, clinical-anamnestic, instrumental and laboratory characteristics including NT-proBNP plasma levels. Patients were monitored in a 6-month-follow-up to record adverse fatal events and their possible correlation with baselin…

MaleTime FactorsMyocardial InfarctionMiddle AgedPrognosisSettore MED/11 - Malattie Dell'Apparato CardiovascolareNT-proBNP myocardial infarctionPeptide FragmentsLogistic ModelsPredictive Value of TestsRisk FactorsNT-proBNPNatriuretic Peptide BrainHumansFemaleBiomarkersAgedFollow-Up StudiesRetrospective Studies
researchProduct

Sleep apnea risk in subjects with asthma with or without comorbid rhinitis

2014

BACKGROUND: As many as 80% of patients with asthma suffer from allergic rhinitis (AR), and rhinitis symptoms are associated with sleep complaints The aim of this cross-sectional study was to assess the prevalence of obstructive sleep apnea syndrome risk in patients with asthma and to explore the association between comorbid rhinitis and obstructive sleep apnea syndrome risk. METHODS: Subjects with asthma were recruited by general practitioners during a control visit. Physicians compiled a questionnaire that assessed the presence of AR according to ARIA (Allergic Rhinitis and Its Impact on Asthma) guidelines and factors influencing the risk of obstructive sleep apnea syndrome (gastroesophage…

MaleTime FactorsSettore MED/10 - Malattie dell'Apparato RespiratorioComorbidityCritical Care and Intensive Care MedicineSeverity of Illness IndexRisk FactorsSurveys and QuestionnairesPrevalenceSurveys and QuestionnaireRhinitisriskSleep Apnea ObstructiveMedicine (all)ApneaSleep apneaGeneral MedicineMiddle Agedsleep apneaFemalemedicine.symptomAllergic rhinitis; Asthma; Obstructive sleep apnea syndrome; Risk; Sleep apnea; STOP-BANG; Pulmonary and Respiratory Medicine; Critical Care and Intensive Care MedicineHumanPulmonary and Respiratory MedicineAdultmedicine.medical_specialtyTime Factorobstructive sleep apnea syndromeAllergicInternal medicineSTOP-BANGSeverity of illnessmedicineAllergic rhinitiHumansAsthmaCross-Sectional Studieallergic rhinitisbusiness.industryObstructiveRisk FactorSTOP-BANG; allergic rhinitis; asthma; obstructive sleep apnea syndrome; risk; sleep apneaOdds ratioasthmamedicine.diseaseObesityComorbidityRhinitis Allergicrespiratory tract diseasesObstructive sleep apneaAllergic rhinitis; Asthma; Obstructive sleep apnea syndrome; Risk; Sleep apnea; STOP-BANG; Adult; Asthma; Comorbidity; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Prevalence; Rhinitis Allergic; Risk Factors; Severity of Illness Index; Sleep Apnea Obstructive; Surveys and Questionnaires; Time FactorsCross-Sectional StudiesPhysical therapybusiness
researchProduct

Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat stu…

2020

Purpose: To report clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery. Methods: This multicentre, retrospective study included patients with DME who received an intravitreal DEX implant 1 month before cataract surgery, ‘precataract DEX’ group, or at the time of cataract surgery, ‘concomitant treatments’ group. Inclusion criteria were a follow-up ≥3 months and ophthalmological examination with optical coherence tomography (OCT) imaging at baseline (cataract surgery) and throughout follow-up. Anatomical improvement was considered to be a decrease in OCT centr…

MaleTime FactorsVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityDexamethasone0302 clinical medicinedexamethasone implantDrug Implantsdiabetescataract surgeryGeneral MedicineTreatment Outcomediabetic macular oedemaIntravitreal InjectionsFemalecataract surgery; dexamethasone implant; diabetes; diabetic macular oedemamedicine.symptomTomography Optical Coherencemedicine.drugmedicine.medical_specialtyCataract ExtractionCataractMacular Edema03 medical and health sciencesOphthalmologyDiabetes mellitusmedicineHumansAdverse effectGlucocorticoidsDexamethasoneAgedRetrospective StudiesDiabetic RetinopathySettore MED/30 - Malattie Apparato Visivobusiness.industryRetrospective cohort studyCataract surgerymedicine.diseaseeye diseasesOphthalmologydiabeteConcomitant030221 ophthalmology & optometryImplantbusiness030217 neurology & neurosurgeryFollow-Up StudiesActa Ophthalmologica
researchProduct

Impact of cardiac rehabilitation exercise program on left ventricular diastolic function in coronary artery disease: a pilot study.

2012

Abstract Diastolic dysfunction is common in coronary artery disease (CAD). Exercise-based cardiac rehabilitation (CR) improves survival and quality of life but its effect on diastolic function is unclear. We sought to determine the impact of CR on diastolic function. We conducted a prospective study of CAD patients referred for 3-month outpatient CR, with pre-CR and post-CR echocardiograms. Twenty-five outpatients (age [mean ± SD], 66 ± 11 years; 7 [28 %] women; 22 [88 %] with recent acute coronary syndrome) were recruited upon beginning CR; one patient lacking follow-up was excluded from analysis. Before CR, patients' mean ejection fraction was 61 ± 7 %; regional wall motion score index wa…

MaleTorsion Abnormalitymedicine.medical_specialtyAcute coronary syndromeTime Factorsmedicine.medical_treatmentDiastolePilot ProjectsCoronary Artery DiseaseVentricular Function LeftCoronary artery diseaseVentricular Dysfunction LeftQuality of lifeDiastoleInternal medicineAmbulatory CareHumansMedicineRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studyCardiac imagingAgedEjection fractionRehabilitationbusiness.industryStroke VolumeRecovery of FunctionMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareExercise Therapycardiac rehabilitationTreatment OutcomeCardiologyFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Vasospastic angina and scombroid syndrome: a case report

2012

Scombroid syndrome is a fish poisoning characterised by the onset of symptoms compatible with a pseudoallergic reaction; it is rarely also responsible of signs and symptoms of acute coronary syndromes, as demonstrated in this case report.

MaleTunaCoronary StenosisCoronary VasospasmAngina scombroid syndromeMiddle AgedCoronary AngiographySettore MED/11 - Malattie Dell'Apparato CardiovascolareAngina PectorisFoodborne DiseasesElectrocardiographyTachycardia SinusAnimalsHumansAngioplasty Balloon CoronaryHistamine
researchProduct

How Have Intravitreal Anti-VEGF and Dexamethasone Implant Been Used in Italy? A Multiregional, Population-Based Study in the Years 2010–2016

2020

Purpose. To describe intravitreal anti-VEGF drug and dexamethasone use in four Italian regions. Methods. Four regional claims databases were used to measure drug prevalence, compare dosing intervals to those recommended in the summary of product characteristics (SPC), and identify switchers. Bilateral treatment and diabetic macular edema (DME) coding algorithms were validated, linking claims with a sample of prospectively collected ophthalmological data. Results. Overall, 41,836 patients received ≥1 study drug in 2010–2016 (4.8 per 10,000 persons). In 2016, anti-VEGF drug use ranged from 0.8 (Basilicata) to 5.7 (Lombardy) per 10,000 persons while intravitreal dexamethasone use ranged from 0…

MaleVascular Endothelial Growth Factor A0301 basic medicineintravitrealAngiogenesis Inhibitorsalgorithm.0302 clinical medicineMedicineSummary of Product Characteristicsmedia_commonAged 80 and overDrug ImplantsvalidationLaser CoagulationRGeneral MedicineMiddle AgedItalyanti-VEGF030220 oncology & carcinogenesisMedicineFemaleclinical dataoriginal articleResearch Articlemedicine.drugDrugmedicine.medical_specialtyArticle Subjectmedia_common.quotation_subjectMEDLINEdexamethasonePharmacyMacular EdemaGeneral Biochemistry Genetics and Molecular BiologyInsurance Claim Review03 medical and health sciencesRanibizumabInternal medicineHumansDosingDexamethasoneAgedDiabetic RetinopathyGeneral Immunology and MicrobiologySettore MED/30 - Malattie Apparato Visivobusiness.industryclaims database030104 developmental biologydrug utilisationMacular Edema; Ranibizumab; Laser CoagulationImplantRanibizumabbusinessBioMed Research International
researchProduct

Angiogenesis in oral lichen planus: an in vivo and immunohistological evaluation.

2010

Oral lichen planus (OLP) is an autoimmune disease with an inflammatory pathogenesis. The angiogenetic phenomenon is a mechanism at the base of the pathogenesis of chronic inflammatory processes. The aim of this research is to evaluate the angiogenetic phenomenon, comparing an in vitro method with an in vivo one. Thirty OLP patients and 30 healthy subjects were enrolled in the study. Immunohistochemical analysis of the vascular-endothelial growth factor (VEGF) and vascular-endothelial adhesion molecules were carried out by the means of primary antibodies and anti-CD34, anti-VEGF, anti-CD106 antigen (VCAM-1) and anti-CD54 antigen (ICAM-1). Capillary density and others capillaroscopic paramete…

MaleVascular Endothelial Growth Factor APathologymedicine.medical_specialtyAngiogenesisImmunologyBiologyMicroscopic AngioscopyPathogenesisNeovascularizationchemistry.chemical_compoundstomatognathic systemIn vivoSettore MED/28 - Malattie OdontostomatologichemedicineImmunology and AllergyHumansOral mucosaangiogenesis Videocapillaroscopy VEGF ImmunohistochemistryAutoimmune diseaseNeovascularization PathologicGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistryCapillariesVascular endothelial growth factorstomatognathic diseasesmedicine.anatomical_structurechemistryCase-Control StudiesOral lichen planusFemalemedicine.symptomCell Adhesion MoleculesLichen Planus OralArchivum immunologiae et therapiae experimentalis
researchProduct

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

2014

AIMS: The aim was to compare the efficacy of intravitreal therapy with bevacizumab and ranibizumab for choroidal neovascularization (CNV) in pathologic myopia (PM). METHODS: This was a prospective multicenter randomized nonblinded trial. RESULTS: In seven centers, 78 eyes were randomized 1:1 to treatment with bevacizumab (group B, 40 eyes) or ranibizumab (group R, 38 eyes) given with an "on demand" regimen (PRN). The mean follow-up was 19 months (SD 2, range 12-24). The mean BCVA at baseline was 0.60 logMAR (20/80 Snellen equivalent, Seq) and 50 letter score (ls). Mean final BCVA was 0.51 LogMAR (20/63 Seq) and 57 ls (p = 0.0009 and p = 0.0002, respectively). In group B, mean basal BCVA was…

MaleVascular Endothelial Growth Factor AVisual Acuity/drug effectsVisual acuitygenetic structuresVisual AcuityAngiogenesis Inhibitorslaw.inventionBevacizumab/therapeutic use0302 clinical medicineRandomized controlled triallawMyopiaMedicineProspective StudiesProspective cohort studyPathological myopiaAged 80 and overMiddle AgedSensory SystemsBevacizumabVascular endothelial growth factor AChoroidal neovascularizationIntravitreal InjectionsMyopia DegenerativeFemalemedicine.symptommedicine.drugAdultmedicine.medical_specialtyBevacizumabNeuroscience(all)CNVBevacizumab; CNV; Pathological myopia; Ranibizumab.Antibodies Monoclonal HumanizedRanibizumab/therapeutic use03 medical and health sciencesCellular and Molecular NeuroscienceOphthalmologyRanibizumabVascular Endothelial Growth Factor A/antagonists & inhibitorsHumansAngiogenesis Inhibitors/therapeutic useIntravitreal bevacizumabAgedpathological myopia CNV bevacizumab ranibizumabSettore MED/30 - Malattie Apparato Visivobusiness.industryTherapeutic effectChoroidal Neovascularization/drug therapyeye diseasesChoroidal NeovascularizationOphthalmologyRegimen030221 ophthalmology & optometryMyopia Degenerative/drug therapysense organsRanibizumabbusiness030217 neurology & neurosurgeryFollow-Up StudiesGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
researchProduct